Tylenol Autism Lawsuit: Latest Updates & Settlement (2026)
Read in 8mins
Litigation Active – Tylenol Cases Are Still Pending
Status: Active – revived on appeal and back before the trial judge, no settlement announced
Docket: MDL No. 3043, In re: Acetaminophen – ASD-ADHD Products Liability Litigation
Court: U.S. District Court for the Southern District of New York, Judge Denise L. Cote
Pending cases: 113 (JPML, as of November 2, 2026)
Next key date: No trial date set
Article Summary
- The Second Circuit revived the cases and denied a rehearing
- Claims link Tylenol in pregnancy to autism and ADH
- Hundreds of other plaintiffs may be able to join the MDL
Few medicines feel as safe during pregnancy as Tylenol. For decades, expectant mothers have taken it for headaches, fevers and everyday aches. Now hundreds of families claim that trusted pill may have played a role in their child's autism or ADHD. A judge threw their cases out, but in 2026 a federal appeals court gave them a second chance. We explain where the fight against Kenvue stands, what it could mean for your family and what compensation might look like.
Free Tylenol Lawsuit Case Review!
Mentioned by
- Major Developments in the Lawsuit History
- Current Status of the Tylenol Litigation
- What Is the Tylenol Lawsuit?
- How Much Money Can I Get Through a Tylenol Autism Lawsuit?
- Predicting the Tylenol Lawsuit Payout per Person
- How Much Is the Tylenol Autism Settlement for Various Levels of Autism?
- Should I File a Tylenol Lawsuit or Join an MDL?
- Has Your Child Been Harmed by Tylenol Exposure?
Major Developments in the Lawsuit History
- October 16, 2026: The Second Circuit refused to rehear the case, keeping in place its July ruling that sent the cases back to Judge Cote.
- July 13, 2026: A federal appeals court vacated the dismissals and found Judge Cote went too far in barring three of the families' experts.
- September 22, 2025: The FDA began a label change noting a possible link between acetaminophen in pregnancy and autism or ADHD, while stating causation is unproven.
- December 18, 2023: Judge Cote barred all five experts the families relied on, leaving them without admissible proof that acetaminophen in pregnancy causes autism or ADHD.
- October 5, 2022: A federal panel combined Tylenol cases from seven federal districts into MDL No. 3043 before Judge Denise L. Cote in Manhattan.
Following the case
33 updatesFull Tylenol Lawsuit Updates Timeline (2022–2026)
Second Circuit Refuses to Rehear Tylenol Appeal
The Second Circuit denied the petition that Kenvue Brands LLC, formerly Johnson & Johnson Consumer Inc., filed in September. Neither the three-judge panel nor the court's active judges, who considered review by the full court, agreed to hear the case again. That leaves in place the July 13 ruling that vacated the judgments and sent the cases back to Judge Cote.
Court Accepts Industry Briefs Backing Rehearing
The Second Circuit granted motions by five outside groups to file amicus briefs, which are arguments from non-parties, in support of the rehearing petition. The groups were the Atlantic Legal Foundation, the National Association of Manufacturers, the U.S. Chamber of Commerce with the American Tort Reform Association, Lawyers for Civil Justice, and PhRMA. Their briefs were filed on September 29, 2026. The Chamber's brief argued Judge Cote had applied Rule 702 correctly.
Tylenol Maker Asks Second Circuit to Rehear Its Ruling
After the court extended its deadline to September 10, Tylenol maker Kenvue Brands LLC, formerly Johnson & Johnson Consumer Inc., petitioned for rehearing of the July 13 decision. It asked the three-judge panel or the full court, called rehearing en banc, to reconsider. The court denied the petition on October 16, 2026.
Show 30 earlier updates
Second Circuit Revives Federal Tylenol Autism Cases
In Rutledge v. Walgreen Co., a three-judge Second Circuit panel vacated the district court's judgments and sent the cases back to Judge Cote. The panel found she exceeded her discretion in barring Drs. Baccarelli, Hollander, and Pearson, but acted within it in barring Drs. Cabrera and Louie. It invited a fresh look at Dr. Ness and upheld the rejection of the preemption defense. The court ruled only on admissibility, not on whether acetaminophen causes autism or ADHD. Kenvue said it would keep defending the cases.
Plaintiffs' Co-Lead Counsel Sanctioned Over Protective Order
Judge Cote granted Kenvue's sanctions motion against co-lead counsel Ashley Keller and his firm, Keller Postman. She found they willfully broke the MDL protective order, which limits how confidential discovery may be used, by filing Kenvue's confidential documents in the State of Texas's case against the company. They were ordered to pay Kenvue's reasonable attorney's fees and filed an appeal the next day. A June 3 order added a $50,000 donation to March of Dimes, due if the ruling becomes final and is not overturned.
Appeals Court Hears Argument on Expert Exclusions
Judges Calabresi, Lynch, and Lee of the Second Circuit heard oral argument in the consolidated appeals, Nos. 24-916 and 24-2594. Families asked the court to reverse the rulings that barred their general causation experts and ended their federal cases. General causation means whether a drug can cause a condition at all.
Kimberly-Clark Agrees to Buy Tylenol Maker Kenvue
Kenvue signed a merger agreement under which Kimberly-Clark will acquire all of its shares. Kenvue's subsidiary Kenvue Brands LLC, formerly Johnson & Johnson Consumer Inc., is the Tylenol defendant in the autism litigation. Shareholders of both companies approved the deal on January 29, 2026. As of Kenvue's quarter ended June 28, 2026, the transaction was still pending.
Texas Attorney General Sues J&J and Kenvue
Texas sued in Panola County, accusing Johnson & Johnson and Kenvue of deceptively marketing Tylenol to pregnant women and of shifting Tylenol liabilities to Kenvue. The state relied on its consumer protection and fraudulent transfer laws. According to Kenvue's quarterly report, in November 2025 the court dismissed both claims against Kenvue Inc. and J&J, plus the transfer claim against Kenvue Brands LLC. A notice of appeal was filed in December 2025.
FDA Begins Acetaminophen Pregnancy Label Change
The FDA began a label change for acetaminophen to reflect studies tying use during pregnancy to a possible higher risk of autism and ADHD in children. It also sent a notice to physicians. Both made clear that causation is unproven and that some studies point the other way. The notice suggested doctors consider limiting acetaminophen for routine low-grade fevers in pregnancy.
Summary Judgment Ends the Remaining Federal Cases
With Dr. Ness excluded, Judge Cote entered summary judgment against the plaintiffs in the ADHD-only cases. She ruled that scattered statements by defense expert Dr. Faraone, even if admissible, were not reliable proof of general causation. Kenvue reported that every case left in the MDL was dismissed in August 2024 and that all cases were on appeal by December 2024.
Court Bars Plaintiffs' ADHD-Only Expert, Dr. Ness
In a second Rule 702 opinion, Judge Cote excluded epidemiologist Dr. Roberta Ness, the expert used by plaintiffs in later-filed cases. Dr. Ness had narrowed her opinion to ADHD. The court found her Bradford Hill analysis was result-driven and that she did not fairly deal with genetic confounding. Defendants had moved to exclude her on March 29, 2024.
Newer Plaintiffs Allowed to Rely on Dr. Ness
On February 1, 2024, plaintiffs in several newly filed cases told the court they had hired epidemiologist Dr. Roberta Ness, who linked prenatal acetaminophen use to ADHD. Judge Cote later issued an order letting plaintiffs whose short form complaints were served on or after January 12, 2024 meet their causation burden by adopting the Ness report in a timely show-cause response.
Final Judgment Entered in About 550 Cases
Relying on the December 2023 expert ruling, Judge Cote entered final judgment for the defendants in the member cases covered by the show-cause order. A later opinion from July 2024 put that number at about 550 cases. The judgment closed those cases in federal court, and the families appealed to the Second Circuit.
Plaintiffs Ordered to Show Why Their Cases Should Not End
Judge Cote ordered plaintiffs to show cause, meaning explain to the court, by February 1, 2024 why final judgment should not be entered in each member case whose short form complaint had been served no later than January 11, 2024. Plaintiffs whose complaints were served later got 21 days from service to argue that the December 2023 expert ruling did not apply to them.
Judge Excludes All Five Plaintiffs' Causation Experts
After hearing argument on December 7, 2023, Judge Cote granted the defendants' motions to bar Drs. Baccarelli, Cabrera, Hollander, Pearson, and Louie under Rule 702, the federal rule on reliable expert testimony. The 148-page opinion said that, without them, plaintiffs lacked admissible evidence that prenatal acetaminophen exposure causes autism or ADHD.
Settlement Scheduling Call Set, Then Postponed
Magistrate Judge Katharine H. Parker, who handles settlement matters in the MDL, scheduled a call for January 4, 2024 to plan settlement talks. On December 30, 2023, plaintiffs' counsel asked to postpone it. On January 2, 2024, the call was adjourned sine die, a legal term meaning without setting a new date.
Plaintiffs' Leadership Team Renewed
The court reappointed the plaintiffs' leadership for another year. Mikal Watts, Ashley Keller, and W. Mark Lanier stayed on as co-lead counsel. Evan Janush and Amanda Hunt joined as committee co-chairs, and Greg Dovel was added to the steering committee.
U.S. Government Declines to Take a Position on the Warning
Judge Cote had invited the United States, including the FDA, to give its views on the warning plaintiffs proposed in April 2023. On this date, just before the Rule 702 deadline, the government declined to file a statement of interest. Its letter pointed to a separate 2023 FDA review concluding that current studies could not establish causation.
Kenvue Fully Separates From Johnson & Johnson
Kenvue became a fully independent company when J&J completed an exchange offer in which some J&J shareholders traded their J&J shares for Kenvue shares J&J owned. Johnson & Johnson Consumer Inc., the Tylenol maker named in the MDL, is now called Kenvue Brands LLC and is a Kenvue subsidiary.
Court Refuses to Certify Early Appeal for JJCI
Judge Cote denied JJCI's request to certify two rulings that rejected its motions to dismiss for an immediate appeal under 28 U.S.C. § 1292(b). She noted that expert motions on general causation would be briefed that fall, with a December hearing if needed, so an early appeal would not move the case forward faster.
Claims Narrowed and Texas-Law Cases Dismissed
After plaintiffs agreed to amend their master complaints, the court dismissed several claim types, including consumer protection and strict liability misrepresentation claims, from member cases filed before July 31, 2023. It adopted an updated short form complaint. It also dismissed earlier cases governed by Texas law, apart from seven cases whose choice-of-law question was set aside for later.
Texas Safe Harbor Defeats One Claim, California Claim Survives
Ruling on retailer motions, the court dismissed Crystal Washington's claims against CVS under a Texas safe harbor law shielding sellers whose over-the-counter drug labels follow FDA rules. It found the law covered tentative FDA monographs too. The same opinion refused to dismiss Makesha Anderson's claims, which arise under California law.
Walmart Loses Innocent Seller Defense
The court rejected Walmart's argument that Tennessee's innocent seller law shielded it from the claims. It did dismiss a standalone apparent manufacturer claim, a theory that treats a store as the maker of a product sold under its own brand.
Mixed Results for JJCI on Two Dismissal Motions
Judge Cote refused to dismiss Cherise Chapman's case for failing to plausibly plead causation or JJCI's knowledge of the risk. In a second opinion, she granted JJCI's motion to drop misrepresentation claims brought under California law, because they did not point to an affirmative false statement.
Consumer Protection Claim Against Walmart Dismissed
In Hatfield v. Walmart, the court dismissed a consumer protection claim as expressly preempted. Express preemption applies when a federal statute directly bars states from adding their own requirements, here for over-the-counter drug labels.
JJCI's Preemption Defense Rejected
Judge Cote turned down a dismissal bid from Tylenol's maker, Johnson & Johnson Consumer Inc. (JJCI), in Chapman v. Walmart. JJCI argued federal drug law barred the warning plaintiffs sought. The court disagreed, reaching the same result it reached for Walmart in November 2022.
General Causation Schedule Set
A scheduling order put the threshold science question first. Plaintiffs' expert reports were due June 16, 2023, defense reports July 14, and Rule 702 motions September 19. The court held the week of December 4, 2023 open for a possible hearing and paused defense responses to broader discovery, such as sales and marketing, until those motions were decided.
State Court Discovery Coordination Order
The court entered a discovery coordination order so lawyers in related state court cases could join discovery in the MDL. It came with a template order that state judges could adopt, while leaving each state court to decide whether that evidence is admissible in its own case.
Short Form Complaint Approved
The court adopted a short form complaint template for families joining the MDL. Rather than restating every allegation, a new plaintiff can adopt the master complaints filed on December 16, 2022 and add details specific to their case.
Plaintiffs' Leadership Appointed and Direct Filing Allowed
The court appointed the plaintiffs' leadership team for one year, with Mikal Watts, Ashley Keller, and W. Mark Lanier as co-lead counsel and Daniel Sullivan as liaison counsel. A separate direct filing order let plaintiffs file straight into the MDL in Manhattan instead of waiting for a transfer.
Defense Leadership Structure Set
The court named Kristen Richer defense liaison counsel for every defendant. It confirmed the Retailer Liaison Committee's members and, because JJCI had joined the litigation, appointed Sarah Johnston as manufacturer liaison.
Walmart's Preemption Motion Denied
In the MDL's first major ruling, Judge Cote refused to dismiss two Equate-brand cases against Walmart. Preemption is a defense claiming federal law overrides state claims. The court held that the general pregnancy warning FDA rules require did not bar extra pregnancy-related warnings on an acetaminophen label.
Federal Tylenol Cases Centralized in New York
The Judicial Panel on Multidistrict Litigation issued a transfer order creating MDL No. 3043 and sending the cases to Judge Denise L. Cote in Manhattan federal court (S.D.N.Y.). At that point the litigation involved 18 actions in seven districts plus 47 related actions. Every responding defendant had opposed centralization.
Current Status of the Tylenol Litigation
In November 2026, the Judicial Panel on Multidistrict Litigation (JPML) reported that there are 113 cases pending in MDL 3043, commonly called the “Tylenol lawsuit.” An appeals court has revived hundreds of cases that were previously dismissed, so the litigation is active again.
In August 2024, Judge Denise Cote entered a summary judgment against the plaintiffs in the remaining cases focused exclusively on ADHD. The month prior, Cote had excluded the plaintiffs’ expert, Dr. Roberta Ness, whose opinions were limited to ADHD. Before this decision, about 550 cases had been closed after Judge Cote barred five causation experts in 2023.
The plaintiffs filed an appeal with the Second Circuit, asking the court to reverse the rulings that barred the causation experts. All cases were on appeal by December 2024.
Finally, on July 13, 2026, the Second Circuit vacated the judgments. It found that Judge Cote exceeded her gatekeeping role. The ruling revived hundreds of previous lawsuits, sending them back to Judge Cote.
The Second Circuit’s ruling concerned whether certain experts could testify. It didn’t rule on whether acetaminophen can cause autism or ADHD. It only found that Judge Cote had overstepped in barring three expert witnesses: Drs. Baccarelli, Pearson and Hollander. It found that her barring of Drs. Cabrera and Louie was warranted, and it also invited a fresh look at Dr. Ness.
In some MDLs, like the Monsanto glyphosate lawsuit, courts have ruled that federal labeling laws invalidate failure-to-warn claims.
In the Tylenol lawsuit, the Second Circuit upheld the rejection of the preemption defense. This was a defense argument claiming that the FDA’s required pregnancy warning barred them from including additional, specific warnings.
After the Second Circuit’s ruling, Kenvue Brands LLC (the maker of Tylenol and defendant in the lawsuit) filed a petition for a rehearing. On October 16, 2026, the Second Circuit denied the petition.Currently, the cases are back before Judge Cote. There haven’t been any settlement announcements, and no trial date has been set.
New Studies on Acetaminophen and Autism
Over the course of the litigation, multiple new studies have come out, and their findings support the plaintiffs. One of the most notable involved a review of 46 separate studies on acetaminophen use during pregnancy. It found that most studies showed a connection between autism (as well as ADHD and other neurodevelopmental disorders) and Tylenol exposure in utero.
What Is the Tylenol Lawsuit?
Tylenol, a widely used over-the-counter (OTC) medicine, is known for its pain-relieving (analgesic) and fever-reducing (antipyretic) properties. It is often recommended for conditions such as headaches, osteoarthritis and cold symptoms. Each week, approximately one-quarter (23%) of the U.S. population uses acetaminophen-containing medications, according to the Consumer Healthcare Products Association (CHPA).
In recent years, a handful of studies suggest that Tylenol use during pregnancy may be associated with neurological and developmental conditions, including autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in children. A study released by the National Institutes of Health (NIH) in 2019 suggested that a child’s exposure to acetaminophen (the generic drug name for the brand name Tylenol) in the mother’s womb may increase the risk of developing ASD and ADHD.
The CDC’s Autism and Developmental Disabilities Monitoring (ADDM) Network found that as of 2022, about one in every 31 eight-year-old children (about 3.2%) was estimated to have autism spectrum disorder (ASD). After the findings, hundreds of Tylenol autism lawsuits have been filed against the manufacturers of Tylenol and retailers.
In a typical Tylenol lawsuit, plaintiffs (parents whose children were diagnosed with ASD and/or ADHD) claim that manufacturers did not sufficiently warn consumers of the side effects of acetaminophen during pregnancy, similar to the Gardasil lawsuits where plaintiffs allege Merck failed to warn users of long-term side effects of the Gardasil vaccine. Many plaintiffs are joining MDLs to take advantage of the power of numbers. The more people join an MDL against Tylenol manufacturers, the more attention it will draw from other people who may have suffered similar harm.
Is the Tylenol Autism Lawsuit Real?
The suggested link between the use of Tylenol and autism has given rise to hundreds of lawsuits on both the federal and state level. The main defendant in the lawsuits is Kenvue Brands, LLC. It was formerly known as Johnson & Johnson Consumer Inc. Kenvue Brands, LLC became a subsidiary of Kenvue after Kenvue fully separated from J&J in August 2023.
Kimberly-Clark agreed to buy Kenvue in 2025, and the deal was still pending as of mid 2026.
In these lawsuits, plaintiffs reference scientific evidence suggesting that the prolonged use of Tylenol during pregnancy increases the risk of autism and ADHD in children.
In October 2025, Texas Attorney General Ken Paxton filed a lawsuit against J&J and Kenvue. The lawsuit, which was filed in Panola County, claimed that the defendants deceptively marketed Tylenol to pregnant women and deliberately shifted liability to Kenvue.
In November 2025, the lawsuit against Kenvue and J&J was dismissed, and so was a transfer claim against Kenvue. Paxton submitted a notice of appeal in December 2025.
How Much Money Can I Get Through a Tylenol Autism Lawsuit?
Many lawsuits against pharmaceutical companies – or, in the case of J&J, pharmaceutical conglomerates – are resolved through a settlement. Parties can reach a settlement either before a lawsuit is filed or during the pre-trial phase after the filing. However, many cases cannot be resolved through a settlement and require a trial. The amount of money you can get through a Tylenol lawsuit — either an individual lawsuit or as part of the ongoing MDL — depends on the specific details of your case and how badly you or your child was affected. Your case could potentially be worth tens or even hundreds of thousands of dollars. This could include compensation for medical bills, emotional distress, lost wages and other damages.
Predicting the Tylenol Lawsuit Payout per Person
No Tylenol autism or ADHD cases have been settled yet, and no trial date has been set, either. That delay can largely be explained by the court process. The defendants successfully had the federal lawsuits dismissed in 2024, and the Second Circuit finally vacated that judgment on July 13, 2026.
Since there are no past awards to predict possible future awards, you must rely on remedies law to estimate them. When you win a lawsuit, you can pursue compensation for both economic and non-economic losses.
Economic losses represent the financial cost of your child’s condition. Medical bills, counseling, lost income and caretaking might qualify as economic losses. Non-economic losses represent the erosion in their quality of life due to their conditions. These compensate your child for their mental anguish and inability to participate in activities.
How Much Is the Tylenol Autism Settlement for Various Levels of Autism?
The major factor that determines the payout is the seriousness of ADHD or Autism disorder and how much a pregnant woman takes acetaminophen. The seriousness and severity of these disorders, especially Autism, are measured in three distinct units: ASD level 1, ASD level 2 and ASD level 3. The first level is less severe, while the third level has greater severity of ASD.
Lawsuit settlements will likely depend on the seriousness of ASD or autism. However, because no bellwether trial has been held yet, estimating exact settlement amounts isn’t possible.
Autism Spectrum Disorder Level 1
Level 1 Autism, often referred to as "high-functioning autism," generally results in lower settlements. Children with this level can articulate well but struggle with social norms and executive functions similar to those with ADHD. However, even children at the lowest level will feel the effects of their condition for their entire lives.
Autism Spectrum Disorder Level 2
For Level 2 Autism, which involves more pronounced communication and behavioral issues, the estimated compensation is higher than that for level 1. These children face challenges in adapting to and deviating from routine activities. As a result, they may need significant treatment and assistance.
Autism Spectrum Disorder Level 3
Level 3 Autism, the most severe form, may lead to the highest possible compensation. Children at this level face extreme difficulties in both verbal and non-verbal communication and are highly restricted in their activities and interactions. These children might need to pay for residential care or full-time caretakers.
Should I File a Tylenol Lawsuit or Join an MDL?
If your child was diagnosed with autism or ADHD and you suspect the use of Tylenol during pregnancy to be the culprit, you may qualify to file a Tylenol lawsuit or join an MDL against Kenvue or other defendants. However, you will need to prove the link between the use of Tylenol and your child’s condition. This may require the assistance of a knowledgeable lawyer who can build a compelling case on your behalf and establish the link between prenatal acetaminophen usage and the child’s autism, ADHD, or other conditions.
Not sure where to find the right lawyer for your case? ConsumerShield can help connect you with lawyers specialized in Tylenol lawsuits so you can better understand your legal rights and options for compensation.
Has Your Child Been Harmed by Tylenol Exposure?
Manufacturers of dangerous drugs must be held accountable for the harm they cause. If you suspect your child was harmed by Tylenol during your pregnancy, you could recover compensation in the future.
A product liability attorney can evaluate your case and help you determine the next steps, and ConsumerShield can help you find the right lawyer for you. Fill out our contact form to get started for free!
Dangerous Drugs Lawsuits Knowledge Base
Kratom Lawsuit
Kratom Lawsuit
Kratom Lawsuit
Kratom Lawsuit
Depo Provera Lawsuit
Depo Provera Lawsuit
Depo Provera Lawsuit
Depo Provera Lawsuit
Depo Provera Lawsuit
Ozempic Lawsuit
Tepezza Lawsuit
Suboxone Lawsuit
Suboxone Lawsuit
Oxbryta Lawsuit
No topics match your search.
Frequently Asked Questions
The main claim in the Tylenol autism lawsuits alleges that in utero exposure to Tylenol may lead to higher rates of autism and other Tylenol-related neurologic disorders in children.
This lawsuit is significant because it allows a group of individuals who share similar claims to collectively pursue legal action against a common defendant, in this case, the manufacturer of Tylenol. Consolidating cases into an MDL can streamline legal proceedings, address common issues efficiently and potentially lead to a collective resolution for affected individuals.
Families who believe they have been affected by the alleged side effects of Tylenol and are considering joining the lawsuit can contact legal representatives who specialize in handling Tylenol lawsuits. These attorneys can provide information, evaluate individual cases and guide families through the process of potentially joining the legal action.
Settlement amounts generally depend on the severity of the autism spectrum disorder (ASD Level 1, 2 or 3) and the extent of acetaminophen use during pregnancy. Economic losses like medical bills and caretaking costs, as well as non-economic losses such as mental anguish and reduced quality of life, may also influence the compensation amount.
Resources
Explore related articles and sources cited on this page.